5

scan0099 - MistNews · 2020. 7. 13. · ibnsinapharma 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 [email protected] 0/0 5 THE EUROPEAN BANK FOR

Download PDF Report

Upload
others
View
2
Download
0

Embed Size (px)

Citation preview

Page 1: scan0099 - MistNews · 2020. 7. 13. · ibnsinapharma 01000852771 44891137 Mohamed.shawky@ibnsinapharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com 0/0 5 THE EUROPEAN BANK FOR

Page 2: scan0099 - MistNews · 2020. 7. 13. · ibnsinapharma 01000852771 44891137 Mohamed.shawky@ibnsinapharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com 0/0 5 THE EUROPEAN BANK FOR

Page 3: scan0099 - MistNews · 2020. 7. 13. · ibnsinapharma 01000852771 44891137 Mohamed.shawky@ibnsinapharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com 0/0 5 THE EUROPEAN BANK FOR

Page 4: scan0099 - MistNews · 2020. 7. 13. · ibnsinapharma 01000852771 44891137 Mohamed.shawky@ibnsinapharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com 0/0 5 THE EUROPEAN BANK FOR

Page 5: scan0099 - MistNews · 2020. 7. 13. · ibnsinapharma 01000852771 44891137 Mohamed.shawky@ibnsinapharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com 0/0 5 THE EUROPEAN BANK FOR

Ibnsina Pharma Releases FY2019 Results EGP 16.6 BN EGP 1.4 BN · Gross profit booked EGP 1.4 billion, up 28.0% year- ... retail pharmaceutical market registeredtotal sales of EGP

Ibnsina Pharma Releases FY2019 Results EGP 16.6 BN EGP 1.4 BN · Gross profit booked EGP 1.4 billion, up 28.0% year- ... retail pharmaceutical market registeredtotal sales of EGP

Documents

Financial Statements-Consolidated - beximco-pharma.combeximco-pharma.com/investor/audited-annual... · Beximco Pharmaceuticals Limited and its Subsidiaries Report on the Audit of

Financial Statements-Consolidated - beximco-pharma.combeximco-pharma.com/investor/audited-annual... · Beximco Pharmaceuticals Limited and its Subsidiaries Report on the Audit of

Documents

Acquisition of Sepracor Inc. - ds-pharma.com

Acquisition of Sepracor Inc. - ds-pharma.com

Documents

191001 Poster HER2 ADCWorld - heidelberg-pharma.com · Title: Microsoft PowerPoint - 191001_Poster HER2_ADCWorld Author: palfi Created Date: 10/2/2019 9:43:23 AM

191001 Poster HER2 ADCWorld - heidelberg-pharma.com · Title: Microsoft PowerPoint - 191001_Poster HER2_ADCWorld Author: palfi Created Date: 10/2/2019 9:43:23 AM

Documents

Peptic ulcer disease - suli-pharma.com ulcer disease 2017.pdf · ! 1! Peptic’ulcer’disease ’! DrKawaAhmad! PhDPharmaceutics!! 1! GIT ! Foodtakenintothemouthismixedwithsalivatoformaplasticmass.Thesalivaryglands

Peptic ulcer disease - suli-pharma.com ulcer disease 2017.pdf · ! 1! Peptic’ulcer’disease ’! DrKawaAhmad! PhDPharmaceutics!! 1! GIT ! Foodtakenintothemouthismixedwithsalivatoformaplasticmass.Thesalivaryglands

Documents

PROGRAM AT A GLANCE 7TH INTERNATIONAL CONGRESS OF …bnpl.org.in/images/PROGRAM_20-01-2020.pdf · CRIUM, Hyderabad, INDIA Topic: Emerging trends in the management of Vitiligo IbnSina

PROGRAM AT A GLANCE 7TH INTERNATIONAL CONGRESS OF …bnpl.org.in/images/PROGRAM_20-01-2020.pdf · CRIUM, Hyderabad, INDIA Topic: Emerging trends in the management of Vitiligo IbnSina

Documents

Ibnsina Pharma Releases Audited FY18 Resultsresources.inktankir.com/isph/ISP-ER-4Q18.pdfand second-largest pharmaceutical distributor, released today its audited results for the fiscal

Ibnsina Pharma Releases Audited FY18 Resultsresources.inktankir.com/isph/ISP-ER-4Q18.pdfand second-largest pharmaceutical distributor, released today its audited results for the fiscal

Documents

Ibnsina Pharma Releases Audited 1H18 Resultsenterprise.press/wp-content/uploads/2018/08/ISP-ER-1H2018-Final.pdf · efficiency have given Ibn Sina control of 19.9% market share in

Ibnsina Pharma Releases Audited 1H18 Resultsenterprise.press/wp-content/uploads/2018/08/ISP-ER-1H2018-Final.pdf · efficiency have given Ibn Sina control of 19.9% market share in

Documents

ISP ER 1Q19 - E - Final · Established in 2001, Ibnsina Pharma “ISP” is the fastest growing, and 2nd largest, pharmaceutical distributor in Egypt with a market share of 19.7%

ISP ER 1Q19 - E - Final · Established in 2001, Ibnsina Pharma “ISP” is the fastest growing, and 2nd largest, pharmaceutical distributor in Egypt with a market share of 19.7%

Documents

January 2015 - Heidelberg Pharma GmbHheidelberg-pharma.com/.../2014/...Biotech-Showcase.pdf · Pharma or Biotech started or completed ADC technology platform for oncology Retain value

January 2015 - Heidelberg Pharma GmbHheidelberg-pharma.com/.../2014/...Biotech-Showcase.pdf · Pharma or Biotech started or completed ADC technology platform for oncology Retain value

Documents

Effects of IL-21, KIR Blockade, and CD137 Agonism on the ...innate-pharma.com/sites/default/files/ash2014_preclinical_poster... · ———Through direct activation and engagement

Effects of IL-21, KIR Blockade, and CD137 Agonism on the ...innate-pharma.com/sites/default/files/ash2014_preclinical_poster... · ———Through direct activation and engagement

Documents

Netnography: A Useful Market Research Tool for ...consulting-for-pharma.com/.../pharma_netnography_cfp_part2.pdf · Does netnography support the success of my medicinal product? 4

Netnography: A Useful Market Research Tool for ...consulting-for-pharma.com/.../pharma_netnography_cfp_part2.pdf · Does netnography support the success of my medicinal product? 4

Documents

Dr. Mohammed N. Sabir 2021 - suli-pharma.com

Dr. Mohammed N. Sabir 2021 - suli-pharma.com

Documents

PROGRAM AT A GLANCE 7TH INTERNATIONAL CONGRESS OF …bnpl.org.in/images/TENTATIVE_TECHNICAL_PROGRAM.pdf · of Vitiligo Dr. Hassan Khalid Al Subki IbnSina University, SUDAN Topic:

PROGRAM AT A GLANCE 7TH INTERNATIONAL CONGRESS OF …bnpl.org.in/images/TENTATIVE_TECHNICAL_PROGRAM.pdf · of Vitiligo Dr. Hassan Khalid Al Subki IbnSina University, SUDAN Topic:

Documents

OIC-VET IbnSina Health Capacity Building Programme ... and Tobacco.pdf · OIC-VET IbnSina Health Capacity Building Programme (IbnSina-HCaB) S ES RIC STATISTICAL ECONOMIC AND SOCIAL

OIC-VET IbnSina Health Capacity Building Programme ... and Tobacco.pdf · OIC-VET IbnSina Health Capacity Building Programme (IbnSina-HCaB) S ES RIC STATISTICAL ECONOMIC AND SOCIAL

Documents

Investor Webinar - investor.xenon-pharma.com

Investor Webinar - investor.xenon-pharma.com

Documents

CLINICAL STUDY REPORT - leo-pharma.comleo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical trial...clinical study report investigation on the acceptability of calcipotriol solution

CLINICAL STUDY REPORT - leo-pharma.comleo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical trial...clinical study report investigation on the acceptability of calcipotriol solution

Documents

scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsinapharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office

scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsinapharma.com 15/12 3/2 [email protected] : 0/0 5 Il Head Office

Documents

Ibnsina Pharma Releases Audited 9M18 Results · Mohamed Shawky Investor Relations Manager Email: mohamed.shawky@ibnsina-pharma.com Shareholding Structure (Post IPO and Capital Increase)

Ibnsina Pharma Releases Audited 9M18 Results · Mohamed Shawky Investor Relations Manager Email: [email protected] Shareholding Structure (Post IPO and Capital Increase)

Documents

PLATFORM - medtech-pharma.com€¦ · EU IVDR - Effect on companion diagnostic development Claudia Dollins, Merck ... Chair: Thomas Kühler, Sanofi Internet-of-Things (IoT) & connectivity

PLATFORM - medtech-pharma.com€¦ · EU IVDR - Effect on companion diagnostic development Claudia Dollins, Merck ... Chair: Thomas Kühler, Sanofi Internet-of-Things (IoT) & connectivity

Documents

Significant progress - Heidelberg Pharma GmbHheidelberg-pharma.com/pdf/Berichte/20100223_WILEX_GB_2009_E.pdf · Cash flow statement Cash flow from operating activities (18,638) (22,830)

Significant progress - Heidelberg Pharma GmbHheidelberg-pharma.com/pdf/Berichte/20100223_WILEX_GB_2009_E.pdf · Cash flow statement Cash flow from operating activities (18,638) (22,830)

Documents

LEO80185-G23 Clinical Study Report 11-Oct-2011leo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical trial... · 11.4.1.1 Primary Endpoint – Controlled Disease According to

LEO80185-G23 Clinical Study Report 11-Oct-2011leo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical trial... · 11.4.1.1 Primary Endpoint – Controlled Disease According to

Documents

9-MONTH FINANCIAL REPORT 2015heidelberg-pharma.com/pdf/Berichte/20151015_WLX_QB_03_2015_e.pdfAfter reporting a very successful first half from a scientific and financial perspective,

9-MONTH FINANCIAL REPORT 2015heidelberg-pharma.com/pdf/Berichte/20151015_WLX_QB_03_2015_e.pdfAfter reporting a very successful first half from a scientific and financial perspective,

Documents

Investor Presentation - Amazon S3 · Presentation FY 2017 Audited Results ... Established in 2001, Ibnsina Pharma “ISP” is the fastest growing, and 2nd largest, pharmaceutical

Investor Presentation - Amazon S3 · Presentation FY 2017 Audited Results ... Established in 2001, Ibnsina Pharma “ISP” is the fastest growing, and 2nd largest, pharmaceutical

Documents

Identification of Organic compoundssuli-pharma.com/uploads/lectures/Identification.pdf · ignition ; elemental analysis; solubility : PH test and classification tests to identify

Identification of Organic compoundssuli-pharma.com/uploads/lectures/Identification.pdf · ignition ; elemental analysis; solubility : PH test and classification tests to identify

Documents

Interim Financial Statements (Un-audited) - Beximco ...beximco-pharma.com/investor/half-yearly-report-2019-2020.pdfBeximco Pharmaceuticals Limited and its Subsidiaries Consolidated

Interim Financial Statements (Un-audited) - Beximco ...beximco-pharma.com/investor/half-yearly-report-2019-2020.pdfBeximco Pharmaceuticals Limited and its Subsidiaries Consolidated

Documents

Corporate Presentation January 2017 - sensorion-pharma.com · Latest development in the histaminergic pathway applied to vertigo treatment – First-in-class Histamine H4 Receptor

Corporate Presentation January 2017 - sensorion-pharma.com · Latest development in the histaminergic pathway applied to vertigo treatment – First-in-class Histamine H4 Receptor

Documents

Physicochemical Properties of Drugs Affecting Bioavailabilitysuli-pharma.com/uploads/lectures/4_Biopharmaceutics.pdf · 2019-11-29 · •Drug Factors affecting dissolution rate •Factors

Physicochemical Properties of Drugs Affecting Bioavailabilitysuli-pharma.com/uploads/lectures/4_Biopharmaceutics.pdf · 2019-11-29 · •Drug Factors affecting dissolution rate •Factors

Documents

Company Update - Heidelberg Pharma GmbHheidelberg-pharma.com/wp-content/uploads/2015/01/... · 2019-06-26 · This communication contains certain forward-looking statements, relating

Company Update - Heidelberg Pharma GmbHheidelberg-pharma.com/wp-content/uploads/2015/01/... · 2019-06-26 · This communication contains certain forward-looking statements, relating

Documents

3-MONTH FINANCIAL REPORT 2009heidelberg-pharma.com/pdf/Berichte/090408_WILEX_QB_01_2009_e.pdf · The planned milestone payments secure the Company’s finan-cing until the first quarter

3-MONTH FINANCIAL REPORT 2009heidelberg-pharma.com/pdf/Berichte/090408_WILEX_QB_01_2009_e.pdf · The planned milestone payments secure the Company’s finan-cing until the first quarter

Documents